Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on August 13, 2024, regarding events occurring on August 9, 2024. The filing addresses the company's compliance with Nasdaq Capital Market listing requirements following the reporting period ended June 30, 2024.
Key Financial Metrics
- Stockholders' Equity (as of June 30, 2024): $2,375,353
- Nasdaq Minimum Equity Requirement: $2,500,000
- Recent Financing Proceeds: Approximately $1.5 million gross
- Shares Sold in Financing: 564,730 shares of common stock
- Financing Mechanism: At the Market Offering Agreement with Ladenburg Thalmann & Co. Inc.
Material Changes
The company reported a stockholders' equity balance below the Nasdaq minimum requirement of $2.5 million in its June 30, 2024 Form 10-Q. Subsequent to that date, the company executed a financing transaction selling 564,730 shares for approximately $1.5 million. Management states that, after giving effect to this transaction, the company now believes it complies with the Stockholders' Equity Requirement.
Outlook, Risks, and Contingencies
Delisting Risk: Nasdaq will continue to monitor the company's ongoing compliance. If the company fails to evidence compliance in its next Quarterly Report on Form 10-Q, its common stock may be subject to delisting.
Management Commentary: The company asserts current compliance based on the recent capital raise but acknowledges the conditional nature of maintaining listing status pending future reporting.
Investor Verification Checklist
- Verify the exact post-transaction stockholders' equity balance in the next Form 10-Q filing.
- Confirm the net proceeds of the $1.5 million financing after deducting offering costs.
- Monitor Nasdaq communications regarding the company's continued listing status.
- Review the company's cash burn rate to assess the sustainability of the new equity level.